Artivion (NYSE:AORT) Announces Quarterly Earnings Results

Artivion (NYSE:AORT) posted its quarterly earnings results on Thursday. The company reported $0.13 earnings per share for the quarter, FiscalAI reports. The business had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%.

Here are the key takeaways from Artivion’s conference call:

• Q2 revenue increased 9% year over year to $125.8 million, while adjusted EBITDA rose 7% to $26.4 million. Stent graft revenue accelerated 12% and On-X revenue grew 18%, both despite tougher comparisons.
• Artivion received FDA PMA approval for AMDS in June, removing IRB-related hurdles and expanding permitted marketing claims; management expects adoption and U.S. account conversions to accelerate gradually in the second half rather than through an immediate surge.
• The company completed its Endospan acquisition and plans a full U.S. launch of the FDA-approved NEXUS aortic arch system in January 2027. Management views NEXUS, AMDS, On-X, and the ARTIZEN pipeline as collectively representing roughly $430 million in current U.S. market opportunity.
• Artivion reiterated 2026 guidance for 7%–11% constant-currency revenue growth, or $480 million–$496 million, and adjusted EBITDA of $92 million–$99 million. The outlook assumes minimal NEXUS revenue this year, continued preservation-services timing and supply constraints, and roughly $8 million of Endospan-related expenses.
• Free cash flow was negative $12 million in Q2, while net leverage rose to 3.1 following $150 million of borrowing to fund the Endospan acquisition; the company also expects the $25 million AMDS milestone payment in Q3 and remains exposed to manufacturing and geopolitical risks tied to Endospan’s Israel facility.

Artivion Trading Up 2.4%

Shares of Artivion stock traded up $0.63 on Friday, reaching $27.20. The company had a trading volume of 1,081,660 shares, compared to its average volume of 597,567. The firm’s 50 day moving average price is $23.52 and its two-hundred day moving average price is $31.13. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. Artivion has a 52-week low of $19.16 and a 52-week high of $48.25. The firm has a market cap of $1.32 billion, a PE ratio of 49.20 and a beta of 1.25.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Needham & Company LLC reissued a “buy” rating and set a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Citizens Jmp cut their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $45.00 target price on Artivion in a research report on Monday, June 1st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.67.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Artivion reported second-quarter revenue of $125.8 million, up 11% year over year and above the approximately $120 million consensus estimate. Non-GAAP earnings were $0.13 per share, matching expectations, while adjusted EBITDA rose 7% to $26.4 million. Artivion Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, a regulatory milestone that could expand its aortic surgery product opportunity. Artivion also completed its acquisition of Endospan Ltd., potentially strengthening its portfolio and long-term growth prospects. Artivion Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Conestoga Capital Advisors highlighted Artivion as a long-term growth opportunity amid improving investor interest in small-cap stocks. The firm’s comments provide supportive institutional sentiment, although they do not represent a new price target or recommendation. Long-Term Growth Opportunities Remain for Artivion (AORT) Despite Challenges
• Neutral Sentiment: Artivion maintained fiscal 2026 revenue guidance of $480 million to $496 million, a range broadly in line with the roughly $486.3 million analyst consensus. The earnings call offered further management commentary on the outlook and recent developments. Artivion Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the adjusted profit, Artivion posted a GAAP net loss of $13.5 million, or $0.28 per share, compared with $0.24 in earnings per share a year earlier. The company’s low 2.55% net margin and elevated valuation could make the stock sensitive to any execution or profitability concerns. Artivion Q2 Earnings Meet Estimates

Insider Buying and Selling at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently modified their holdings of AORT. Caitong International Asset Management Co. Ltd acquired a new position in Artivion in the 3rd quarter valued at about $27,000. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Artivion in the fourth quarter valued at approximately $79,000. Quadrant Capital Group LLC purchased a new position in shares of Artivion in the third quarter valued at approximately $92,000. Finally, iSAM Funds UK Ltd acquired a new position in shares of Artivion in the third quarter valued at approximately $131,000. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.